Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Baker Bros. Advisors and Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Baker Bros. Advisors 5,032,313 0 5,032,313 0 5,032,313 15.2%
Baker Bros. Advisors (GP) 5,032,313 0 5,032,313 0 5,032,313 15.2%
Felix J. Baker 5,032,313 0 5,032,313 0 5,032,313 15.2%
Julian C. Baker 5,032,313 0 5,032,313 0 5,032,313 15.2%
Julian Baker And Felix Baker
Julian Baker And Felix Baker
Baker Bros. Advisors

Page 1 of 10 – SEC Filing

SCHEDULE 13G

SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, DC 20549

Under the
Securities Exchange Act of 1934

(Amendment No.    )*

Bellicum Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

079481107

(CUSIP Number)

Not Applicable

(Date of Event which Requires Filing of
this Statement)

Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)
¨ [Rule 13d-1(c)
¨ Rule 13d-1(d)

* The remainder
of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior
cover page.

The information
required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the
Act, but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 10 Pages

Follow Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)
Trade (NASDAQ:BLCM) Now!
Loading...